Perceptive Advisors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $8.57M | Sell |
65,050
-266,000
| -80% | -$35.3M | 0.17% | 68 |
|
|
2025
Q4 | $47M | Sell |
331,050
-119,000
| -26% | -$17.2M | 0.84% | 37 |
|
|
2025
Q3 | $63.2M | Buy |
450,050
+195,000
| +76% | +$26.4M | 1.82% | 18 |
|
|
2025
Q2 | $32.1M | Buy |
255,050
+155,000
| +155% | +$17.8M | 1.19% | 23 |
|
|
2025
Q1 | $11.1M | Hold |
100,050
| – | – | 0.39% | 48 |
|
|
2024
Q4 | $13.7M | Sell |
100,050
-112,178
| -53% | -$13.9M | 0.38% | 51 |
|
|
2024
Q3 | $24.5M | Sell |
212,228
-437,681
| -67% | -$60M | 0.52% | 50 |
|
|
2024
Q2 | $89.5M | Sell |
649,909
-154,500
| -19% | -$21.2M | 2.16% | 11 |
|
|
2024
Q1 | $111M | Buy |
804,409
+533,615
| +197% | +$72.9M | 1.94% | 15 |
|
|
2023
Q4 | $35.7M | Buy |
270,794
+111,552
| +70% | +$12.8M | 0.8% | 39 |
|
|
2023
Q3 | $17.9M | Buy |
159,242
+59,192
| +59% | +$6.23M | 0.6% | 46 |
|
|
2023
Q2 | $9.43M | Hold |
100,050
| – | – | 0.27% | 66 |
|
|
2023
Q1 | $10.1M | Hold |
100,050
| – | – | 0.3% | 66 |
|
|
2022
Q4 | $11.9M | Hold |
100,050
| – | – | 0.34% | 58 |
|
|
2022
Q3 | $10.6M | Sell |
100,050
-297,838
| -75% | -$30.2M | 0.31% | 64 |
|
|
2022
Q2 | $38.8M | Buy |
397,888
+2,249
| +0.6% | +$208K | 1.21% | 22 |
|
|
2022
Q1 | $37.1M | Sell |
395,639
-87,368
| -18% | -$7.4M | 0.74% | 36 |
|
|
2021
Q4 | $41.1M | Hold |
483,007
| – | – | 0.63% | 41 |
|
|
2021
Q3 | $46.3M | Sell |
483,007
-328,825
| -41% | -$31.1M | 0.67% | 37 |
|
|
2021
Q2 | $79M | Sell |
811,832
-130,000
| -14% | -$12.5M | 1.03% | 27 |
|
|
2021
Q1 | $91.6M | Sell |
941,832
-957,383
| -50% | -$100M | 1.16% | 24 |
|
|
2020
Q4 | $182M | Buy |
1,899,215
+350,500
| +23% | +$33.9M | 1.95% | 12 |
|
|
2020
Q3 | $149M | Sell |
1,548,715
-592,695
| -28% | -$68.6M | 2.17% | 14 |
|
|
2020
Q2 | $261M | Sell |
2,141,410
-921,853
| -30% | -$102M | 4.23% | 6 |
|
|
2020
Q1 | $265M | Sell |
3,063,263
-549,291
| -15% | -$53.8M | 6.91% | 3 |
|
|
2019
Q4 | $388M | Sell |
3,612,554
-447,346
| -11% | -$46.8M | 7.71% | 3 |
|
|
2019
Q3 | $366M | Buy |
4,059,900
+36,038
| +0.9% | +$3.37M | 9.86% | 1 |
|
|
2019
Q2 | $340M | Buy |
4,023,862
+265,200
| +7% | +$21.8M | 7.8% | 1 |
|
|
2019
Q1 | $331M | Sell |
3,758,662
-849,892
| -18% | -$71M | 9.34% | 1 |
|
|
2018
Q4 | $315M | Sell |
4,608,554
-168,700
| -4% | -$16.2M | 12% | 1 |
|
|
2018
Q3 | $587M | Buy |
4,777,254
+62,004
| +1% | +$7.03M | 15.71% | 1 |
|
|
2018
Q2 | $463M | Sell |
4,715,250
-46,739
| -1% | -$4.18M | 12.14% | 1 |
|
|
2018
Q1 | $395M | Sell |
4,761,989
-389,600
| -8% | -$32.9M | 11.06% | 1 |
|
|
2017
Q4 | $400M | Buy |
5,151,589
+360,000
| +8% | +$24.6M | 13.25% | 1 |
|
|
2017
Q3 | $294M | Buy |
4,791,589
+1,214,000
| +34% | +$64.1M | 11.22% | 1 |
|
|
2017
Q2 | $165M | Buy |
3,577,589
+211,059
| +6% | +$10.2M | 8.28% | 2 |
|
|
2017
Q1 | $146M | Buy |
3,366,530
+50,007
| +2% | +$2.14M | 8.3% | 1 |
|
|
2016
Q4 | $128M | Buy |
3,316,523
+840,251
| +34% | +$38M | 9.13% | 1 |
|
|
2016
Q3 | $125M | Sell |
2,476,272
-321,695
| -11% | -$16M | 8.09% | 2 |
|
|
2016
Q2 | $127M | Buy |
2,797,967
+77,000
| +3% | +$3.55M | 8.82% | 2 |
|
|
2016
Q1 | $108M | Buy |
2,720,967
+224,800
| +9% | +$8.92M | 9.44% | 2 |
|
|
2015
Q4 | $141M | Sell |
2,496,167
-446,800
| -15% | -$22.7M | 10.45% | 2 |
|
|
2015
Q3 | $117M | Sell |
2,942,967
-341,500
| -10% | -$16.5M | 9.35% | 2 |
|
|
2015
Q2 | $157M | Sell |
3,284,467
-456,800
| -12% | -$19.4M | 9.45% | 2 |
|
|
2015
Q1 | $149M | Buy |
3,741,267
+176,000
| +5% | +$6.3M | 11.55% | 2 |
|
|
2014
Q4 | $79.6M | Sell |
3,565,267
-1,000,000
| -22% | -$18.9M | 6.68% | 2 |
|
|
2014
Q3 | $71.5M | Sell |
4,565,267
-34,600
| -0.8% | -$517K | 7.24% | 2 |
|
|
2014
Q2 | $68.3M | Sell |
4,599,867
-19,500
| -0.4% | -$275K | 6.7% | 2 |
|
|
2014
Q1 | $74.4M | Buy |
4,619,367
+435,630
| +10% | +$7.45M | 7.81% | 2 |
|
|
2013
Q4 | $39.1M | Sell |
4,183,737
-86,967
| -2% | -$849K | 4.69% | 6 |
|
|
2013
Q3 | $48.3M | Sell |
4,270,704
-811,013
| -16% | -$11.1M | 3.92% | 8 |
|
|
2013
Q2 | $68M | Buy |
+5,081,717
| New | +$62.4M | 6.86% | 3 |
|
Other funds holding NBIX
VPM
VCM
Perceptive Advisors's NBIX Position: Q1 2026 in Review
Perceptive Advisors reduced its Neurocrine Biosciences (NBIX) stake by 80% in Q1 2026, selling an estimated $35.3M and leaving 65,050 shares worth $8.57M. The position accounts for 0.17% of the portfolio, ranked #68.
Perceptive Advisors first reported a position in NBIX in Q2 2013 and has held it in 52 quarters since. The position peaked at $587M in Q3 2018. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Perceptive Advisors held 65,050 shares of Neurocrine Biosciences worth $8.57M as of Q1 2026.
- Perceptive Advisors sold 266,000 Neurocrine Biosciences shares in Q1 2026, an estimated $35.3M.
- Neurocrine Biosciences made up 0.17% of Perceptive Advisors's portfolio in Q1 2026, its #68 holding.
- Perceptive Advisors first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 52 quarters since.
- Perceptive Advisors's Neurocrine Biosciences position peaked at $587M in Q3 2018.
- 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.